Chongqing Pharmaceutical Research Institute was founded in 1950 andused to be a leading public institution fully dedicated to pharmaceutical research and development in Southwest China. In 2001, it underwent a historical event that the ownership of CPRI was converted to jointly owned by Shanghai Fosun Pharmaceutical (Group) Co., Ltd and Chongqing Pharmaceutical (Group) Co., Ltd, whereby Chongqing Pharmaceutical Research Institute Co., Ltd was founded (hereinafter referred to as the CPRI).
After decades of development, CPRI had built an integrated new drug development system with full and multi cross-disciplinary supports, including innovative drug (API and Formulation) development, pharmacological and toxicological evaluation, CRO services and pilot level scale-up manufacturing sites complying with the cGMP requirements;also, a Chiral Drug R&D platform; a Drug Delivery System （DDS）platform featured in taste-masked drug delivery technology, targeted and controlled release technology and mucosa and transdermal drug delivery technology and an incubation platform for new medicament product industrialization have been built. Meanwhile, CPRI was officially recognized as a state-level high-tech enterprise, the state-level Enterprise Technology Center (FosunPharma Group), Innovative enterprises in Chongqing, Chongqing Chemical Pharmaceutical Engineering Technology Research Center in Chongqing andNew Drug Delivery System Engineering Technology Research Center in Chongqing.
With a registered capital of 55 million CNY, CPRI employs over 300 staffs consists of about 170 professionals, amongst of which, bachelors and above personnel is over 180, accounting for more than 60% of total employees, also, professor of engineering 6, senior engineer 27 with an average ages of 35, led by a sophisticated R&D and management team consists of new drug evaluation experts, overseas scientists and senior engineers.
CPRI has a total area of more than 9,000 ㎡laboratory for research and development purposes, equipped with state-of-the-art analysis devices and other 1000+ analysis and testing equipment for routine test purposes. Over 30 projects are ongoing and more than 30 million CNY was invested into scientific research activities each year. More than 80% products manufactured by API pilot manufacturing site export to US/EU market, key products have beenrespectively inspected and / or approved by US FDA, CFDA, EDQM, Korea FDA, Japen PMDA andAustralia TGA.
In recent decades, CPRI submitted more than 250 patent files (23 files amongst which submitted under PCT framework and 27files in national phase worldwide) in total. 81 files were granted for Chinese patents and 19 granted for foreign patents.
To survive and flourish in the coming opportunities and challenges, CPRI will be adhering to "Cooperation, Passion, Responsibility, Innovation" as our entrepreneurship, and to build robust proprietary intellectual property worldwide around innovative drugs research activities by developing and implementing an effective talent, patent portfolio management and internationalization strategy. By forging a unique and outstanding drug development technology, CPRI commits to establishing a robust, standardized, prominent and internationally acceptable drug R&D and industrialization system, whereby a first-tier, internationalized and innovation driven hi-tech enterprise could rely upon.
